Viking Therapeutics Inc [NASDAQ: VKTX] stock went on an upward path that rose over 4.05% on Wednesday, amounting to a one-week price increase of more than 5.60%.
Over the last 12 months, VKTX stock dropped by -17.00%. The one-year Viking Therapeutics Inc stock forecast points to a potential upside of 62.71. The average equity rating for VKTX stock is currently 1.21, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $3.75 billion, with 112.29 million shares outstanding and 108.96 million shares in the current float. Compared to the average trading volume of 3.57M shares, VKTX stock reached a trading volume of 5594436 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Viking Therapeutics Inc [VKTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VKTX shares is $89.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VKTX stock is a recommendation set at 1.21. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Viking Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 29, 2025. While these analysts kept the previous recommendation, Goldman raised their target price to Neutral. The new note on the price target was released on April 08, 2025, representing the official price target for Viking Therapeutics Inc stock. Previously, the target price had yet another raise to $102, while Scotiabank analysts kept a Sector Outperform rating on VKTX stock.
The Price to Book ratio for the last quarter was 4.43, with the Price to Cash per share for the same quarter was set at 7.58.
VKTX Stock Performance Analysis:
Viking Therapeutics Inc [VKTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.60. With this latest performance, VKTX shares gained by 34.35% in over the last four-week period, additionally plugging by 1.61% over the last 6 months – not to mention a drop of -17.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VKTX stock in for the last two-week period is set at 69.81, with the RSI for the last a single of trading hit 1.62, and the three-weeks RSI is set at 1.64 for Viking Therapeutics Inc [VKTX]. The present Moving Average for the last 50 days of trading for this stock 28.30, while it was recorded at 32.30 for the last single week of trading, and 37.70 for the last 200 days.
Viking Therapeutics Inc (VKTX) Capital Structure & Debt Analysis
According to recent financial data for Viking Therapeutics Inc. ( VKTX), the Return on Equity (ROE) stands at -14.40%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -13.98%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Viking Therapeutics Inc’s Return on Invested Capital (ROIC) is -15.13%, showcasing its effectiveness in deploying capital for earnings.
Viking Therapeutics Inc (VKTX) Efficiency & Liquidity Metrics
Based on Viking Therapeutics Inc’s (VKTX) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Viking Therapeutics Inc (VKTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Viking Therapeutics Inc. (VKTX) effectively leverages its workforce, generating an average of -$3562222.22 per employee. The company’s liquidity position is robust, with a Current Ratio of 44.25% and a Quick Ratio of 44.25%, indicating strong ability to cover short-term liabilities.
Viking Therapeutics Inc [VKTX] Institutonal Ownership Details
There are presently around $70.12%, or 71.66% of VKTX stock, in the hands of institutional investors. The top three institutional holders of VKTX stocks are: FMR LLC with ownership of 16.54 million shares, which is approximately 14.9835%. VANGUARD GROUP INC, holding 10.1 million shares of the stock with an approximate value of $$535.26 million in VKTX stocks shares; and VANGUARD GROUP INC, currently with $$319.45 million in VKTX stock with ownership which is approximately 5.4589%.
